original ) (raw )CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
Andy Trotti
Seminars in Radiation Oncology, 2003
View PDFchevron_right
Evaluation of Interobserver and Interscale Agreement in Assessing Late Bowel Toxicity after Pelvic Radiation in Patients with Carcinoma of the Cervix
Biji Thomas , Dr Rahul Krishnatry
Japanese Journal of Clinical Oncology, 2013
View PDFchevron_right
Electronic and Paper Collection of Patient-Reported Toxicity in Patients Treated With Pelvic Radiation Therapy: A Prospective Feasibility Study
Alexandra Gilbert
International Journal of Radiation Oncology Biology Physics, 2016
View PDFchevron_right
Development of a Set of Nomograms to Predict Acute Lower Gastrointestinal Toxicity for Prostate Cancer 3D-CRT
Michele Stasi
International Journal of Radiation Oncology Biology Physics, 2008
View PDFchevron_right
Montemurro et al 2015 Adverse Effects Jama Oncology
paola berchialla
View PDFchevron_right
Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Sandra Mitchell
JAMA Oncology, 2015
View PDFchevron_right
Clinical significance of patient-reported questionnaire data: another step toward consensus
David Cella
Journal of Clinical Epidemiology, 2005
View PDFchevron_right
Physical Performance, Toxicity, and Quality of Life as Assessed by the Physician and the Patient
Vahur Valvere
Acta Oncologica, 2002
View PDFchevron_right
Health-related quality of life in the Phase III LUME-Colon 1 study: comparison and interpretation of results from EORTC QLQ-C30 analyses
Ingolf Griebsch
Clinical Colorectal Cancer
View PDFchevron_right
Developing a CTCAEs patient questionnaire for late toxicity after head and neck radiotherapy
Nick Slevin
European Journal of Cancer, 2009
View PDFchevron_right
Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Sandra Mitchell
American Society of Clinical Oncology Educational Book, 2016
View PDFchevron_right
Quality of life in oncology clinical trials: present and future challenges
Andrew Bottomley
Expert Review of Pharmacoeconomics & Outcomes Research, 2002
View PDFchevron_right
The EORTC QLQ-C30 Scoring Manual Published by: European Organisation for Research and Treatment of Cancer
Andrew Bottomley
View PDFchevron_right
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
Sandra Mitchell , Alice Chen
Journal of the National Cancer Institute, 2014
View PDFchevron_right
Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial
Sandra Mitchell
International journal of radiation oncology, biology, physics, 2017
View PDFchevron_right
Predictors of late bowel toxicity using three different methods of contouring in patients undergoing post-operative radiation for cervical cancer
Supriya Chopra
The British Journal of Radiology, 2015
View PDFchevron_right
Calibration of Quality-Adjusted Life Years for Oncology Clinical Trials
Heidi Nelson , Daniel Sargent
Journal of Pain and Symptom Management, 2013
View PDFchevron_right
Health-related quality of life as an endpoint in oncology phase I trials: a systematic review
Isabelle Le Ray
BMC Cancer, 2019
View PDFchevron_right
Predictors of Grade 3 or Higher Late Bowel Toxicity in Patients Undergoing Pelvic Radiation for Cervical Cancer: Results From a Prospective Study
Siji Nojin Paul
International Journal of Radiation Oncology*Biology*Physics, 2014
View PDFchevron_right
Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase
Corina Doța
Clinical pharmacology and therapeutics, 2014
View PDFchevron_right
A method to summarize toxicity in cancer randomized clinical trials
Mayte Suarez-Farinas
Clinical cancer research : an official journal of the American Association for Cancer Research, 2018
View PDFchevron_right
Use of PRO measures to inform tolerability in oncology trials: Implications for clinical review, IND safety reporting and clinical site inspections
Richard Piekarz
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017
View PDFchevron_right
Comparison of patient-reported late treatment toxicity (LENT-SOMA) with quality of life (EORTC QLQ-C30 and QLQ-H&N35) assessment after head and neck radiotherapy
Nick Slevin
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2010
View PDFchevron_right
Quality of Life Outcomes in Patients with Anal Cancer after Combined Radiochemotherapy
Frederik Wenz
Strahlentherapie und Onkologie, 2011
View PDFchevron_right
Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer
Ronald Chen
Cancer, 2010
View PDFchevron_right
Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Doris Howell
Oncology and Therapy, 2018
View PDFchevron_right
Treatment-related harms: What was planned and what was reported? National Cancer Institute's Co-operative group phase III randomized controlled trials: a systematic review
Ben Djulbegovic
Journal of Clinical Epidemiology, 2014
View PDFchevron_right
Health-Related Quality of Life in EORTC clinical trials — 30 years of progress from methodological developments to making a real impact on oncology practice
Andrew Bottomley
European Journal of Cancer Supplements, 2012
View PDFchevron_right